|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
We have shown that an inhaled glucocorticosteroid (GS) causes
1-adrenergic antagonist-blockable, rapid, and transient bronchial vasoconstriction in healthy and asthmatic subjects. Steroids inhibit norepinephrine (NE) uptake by non-neuronal cells,
thereby increasing NE concentration at
-adrenergic receptor
sites. This could explain the GS-induced bronchial vasoconstriction. We therefore studied expression of the steroid-sensitive extraneuronal monoamine transporter (EMT) and steroid
sensitivity of NE uptake in human bronchial artery and rabbit
aorta (as a substitute for the limited supply of human bronchial artery). NE uptake was measured using a semiquantitative, sucrose-potassium phosphate-glyoxylic acid fluorescence
method that we newly adapted for use in single cells. Both human bronchial arteries and rabbit aorta expressed messenger
RNA for EMT, and steroids blocked NE uptake into freshly dissociated human bronchial arterial and rabbit aortic smooth-muscle cells (SMCs). In the latter, inhibition of NE uptake by
steroids was not altered, either by a protein synthesis inhibitor (cycloheximide) or by a transcription inhibitor (actinomycin D), and corticosterone made membrane-impermeant by
conjugation to bovine serum albumin inhibited NE uptake
equipotently. These data show that NE uptake into bronchial
arterial and rabbit aortic SMCs is sensitive to steroids, possibly
mediated by EMT, and suggest a mechanism for GS-induced
bronchial vasoconstriction.
| |
Introduction |
|---|
|
|
|---|
The sympathetic nervous system provides the main nervous control of the bronchial vasculature that is the principal vascular supply to the airway wall (1). Norepinephrine
(NE) released from sympathetic nerve endings leads to
bronchial vasoconstriction via
-adrenergic receptors. The
time that extracellular NE occupies its receptor is a critical
determinant of the magnitude and duration of bronchial
vasoconstriction and is determined mainly by specialized cellular uptake processes (2). These mechanisms include
neuronal and non-neuronal membrane transporters, which
are thus responsible for the functional inactivation of NE
(3, 4). The NE metabolizing enzymes, namely catecholamine-O-methyltransferase (COMT) and monoamine oxidase (MAO), reside intracellularly. Therefore, they are
not involved in NE's initial, functional inactivation. Three
non-neuronal NE transporters have been cloned and characterized: organic cation transporter (OCT) 1 (5), OCT2
(8), and the extraneuronal monoamine transporter (EMT
or OCT3) (11). Although these NE transporters and
their functions have been studied in detail in other tissues
(14), little is known about transporter expression and
non-neuronal NE uptake mechanism in the human bronchial vasculature.
We have shown that an inhaled glucocorticosteroid
(GS) causes a rapid,
1-adrenoceptor-mediated decrease
in bronchial blood flow in vivo (17), the mechanism of
which is unknown. We hypothesized that GSs inhibited
NE uptake by bronchial arterial smooth-muscle cells (SMCs),
thereby increasing the concentration and prolonging the
duration of NE at
-adrenergic receptors and causing vasoconstriction. This hypothesis was supported by the facts
that inhibition of non-neuronal NE uptake has been
shown to increase NE at its active site in vitro (18) and that
EMT, a steroid-sensitive NE uptake transporter, has been
found in several systemic arteries (19).
To examine the presence of a steroid-sensitive, non-neuronal NE uptake in the human bronchial circulation, we evaluated whether EMT messenger RNA (mRNA) is expressed in human bronchial arteries and whether NE uptake into freshly isolated human bronchial arterial SMCs occurs and is sensitive to steroids. These experiments were carried out on conduit-type arteries of the bronchial circulation because smaller vessels (arterioles and small arteries) could not be obtained. To further characterize the action of steroids on NE uptake, we used rabbit aortic SMCs as a substitute for the limited supply of bronchial arterial SMCs.
| |
Materials and Methods |
|---|
|
|
|---|
Materials
All materials were obtained from Sigma Chemical Co. (St. Louis, MO) unless otherwise noted.
Human Bronchial Arteries
Donor lungs found unsuitable for transplantation were obtained through the University of Miami Organ Procurement Program with approval from the local Institutional Review Board. Major branches of bronchial arteries (approximately 2 mm diameter) from the left main bronchus were dissected and the adventitia was removed. To confirm that the dissected structure was in fact an artery, a portion of each vessel was fixed in 4% phosphate-buffered formaldehyde and processed according to regular procedures for histology. Sections were stained with hematoxylin and eosin. The endothelium was removed from the rest of the dissected vessels with a small brush. Then, the pieces (approximately 20 mm long) were used immediately for RNA extraction or cell isolation.
Rabbit Aorta
Adult female New Zealand albino rabbits (3 to 4 kg) were killed by an overdose of pentobarbital sodium according to protocols approved by the University's Institutional Animal Care and Use Committee. The thoracic aorta was excised, adhering fat and connective tissue were removed, and the vessel was opened longitudinally. Endothelial cells were removed by carefully scraping the inside surface of the vessel, and 1-mm-wide strips of the smooth-muscle layer were separated from the adventitia. A total of 15 to 20 strips (approximately 1 × 10-mm pieces) were cut transversely from the muscle preparation and were used immediately for RNA extraction and cell isolation.
Reverse Transcriptase/Polymerase Chain Reaction
Total RNA from human and rabbit vascular smooth muscle was extracted using the Ultraspec RNA Isolation System (Biotecx Laboratories, Houston, TX), treated with deoxyribonuclease (DNase I Amplification Grade; Life Technologies, Rockville, MD), precipitated with ethanol, and quantitated spectrophotometrically at 260 nm. RNA (0.5 µg) was used for first-strand complementary DNA (cDNA) synthesis with Superscript II RT (Life Technologies). Oligonucleotide primers for polymerase chain reactions (PCRs) were designed on the basis of regions of sequence similarity between human, rat, and mouse EMT cDNAs. PCRs (35 cycles of 30 s at 94°C, 45 s at 61°C, and 1 min at 72°C, followed by final elongation of 10 min at 72°C) were done with 5'-CTG GGT GGT CCC TGA GTC TCC-3' (forward) and 5'-TCC CAG GCG CAT GAC AAG TCC-3' (reverse) primers using Taq DNA polymerase (Life Technologies). The predicted size of the reverse transcriptase (RT)-PCR products was 265 base pairs. Control reactions were performed in the absence of RT.
DNA Sequencing and Analysis
RT-PCR products were electrophoresed on ethidium bromide- stained 2% SeaKem agarose (BMA, Rockland, ME) gels, purified on a silica spin column (QiAquick PCR Purification Kit; Qiagen, Valencia, CA), and sequenced by the University of Miami DNA Core Laboratory. Sequences were compared with the published EMT cDNA sequences (human: GenBank accession #AJ001417; rat: GenBank accession #AF055286; mouse: GenBank accession #AF078750) by PileUp (Wisconsin Package; GCG, Madison, WI).
SMC Isolation
SMC isolations from human and rabbit vascular smooth muscle were carried out on the basis of the method of Clapp and Gurney (23) with some modifications. To dissociate cells, muscle strips were transferred to constantly oxygenated incubation solution (137 mM NaCl, 10 mM NaHCO3, 0.2 mM NaH2PO4, 5.4 mM KCl, 0.5 mM KH2PO4, 6 mM glucose, 0.15 mM CaCl2, 2 mM MgCl2, 10 mM N-2-hydroxyethylpiperazine-N'-ethane sulfonic acid, and 0.02% bovine serum albumin [BSA], pH 7.0) containing papain (4 mg/ml) and dithiothreitol (2 mM), and were incubated at 37°C for 60 min with shaking. At the end of the dissociation period, individual SMCs were obtained by gentle titration followed by filtration through a wire sieve (500 µm pore size). To eliminate papain from the solution, cells were collected by centrifugation at 150 × g for 3 min and resuspended in fresh incubation solution. The viability of freshly isolated SMCs after enzymatic dispersion was greater than 95%, as determined by trypan blue exclusion.
NE Uptake Experiments
Freshly prepared SMCs were equilibrated in incubation solution for 30 min at 37°C. For NE uptake experiments, cells were exposed to incubation solution with or without defined NE concentrations and with or without different inhibitors at 37°C. To investigate the effects of pargyline, Ro-41-0960, cycloheximide, and actinomycin D, these drugs were added into the incubation solution 30 min before the NE uptake experiments. Steroid hormones, cycloheximide, and actinomycin D were dissolved in ethanol and freshly diluted into the incubation solution just before use. The final concentration of ethanol never exceeded 0.04%, a concentration with no significant effects on any of the measurements. At the end of the incubation period, SMCs were centrifuged at 150 × g for 3 min, followed by resuspension in 0.3 ml ice-cold, high KCl (20 mM)-containing incubation solution. The SMC suspension was then deposited onto a poly-L-lysine-coated slide and the cells were allowed to settle for 10 min at 4°C before estimating the intracellular NE concentration.
Intracellular NE was visualized using a sucrose-potassium phosphate-glyoxylic acid (SPG) method described for tissue slices (24) and adapted by us for use in isolated cells. This method is based on the cyclization of ethylamine side chains of monoamines by highly reactive aldehydes (glyoxylic acid) in the presence of heat to produce 2-carboxymethyl-dihydroisoquinoline compounds that fluoresce under suitable illumination (25). Slides with SMCs processed as indicated earlier were dipped into SPG solution (0.2 M sucrose, 0.236 M KH2PO4, and 1% glyoxylic acid monohydrate, titrated to pH 7.4 with 1 N NaOH) at room temperature for 3 s. Excess fluid was removed and the slide was placed under a flow of cool air. After 5 min of air-drying, the specimen was covered with a drop of light mineral oil and the slide was sealed with a coverslip and put into an oven at 95°C for 2.5 min. To observe and quantitate fluorescence, a Nikon Eclipse E600FN microscope (Nikon, Melville, NY) with a Lambda DG-4 excitation system (Sutter Instruments, Novato, CA), a cooled CCD camera (Quantix; Photometrics, Tucson, AZ), and Isee software from Inovision, Inc. (Durham, NC), were used. Cells were imaged at original magnification ×600 (5 to 25 cells/field) with differential-interference-contrast (DIC) microscopy, and individual cells were identified as regions of interest. For quantitation of the SPG fluorescence (or intracellular NE concentration) in these cells (or regions of interest), a 10-nm-wide filter centered on 405 nm was used for excitation and the emission was measured at > 455 nm using a long-pass filter (emission maximum: 480 nm), integrating the signal for 1 s. The cooled CCD camera was always set to a predefined gain (held constant throughout the experiments). If possible, the fluorescence of all SMCs on a slide (approximately 50) was measured, which could usually be accomplished by selecting six different, well-separated regions on each slide. Each single cell's mean fluorescence intensity value (FN), expressed in arbitrary units, was corrected for background fluorescence by subtracting the mean FN of SMCs from the same tissue not exposed to NE. Average NE uptake of each experimental group was calculated using the mean normalized FN of all cells. On each experimental day, a control experiment with 20 min of incubation with 50 µM NE was carried out to confirm an intact NE uptake mechanism (positive controls).
Statistics
Results are expressed as means ± standard error of the mean (SEM) with N and n representing numbers of cells and experiments, respectively. Statistical significance determined with analysis of variance was followed by a pairwise comparison with the Tukey-Kramer honestly significant difference post hoc test. P < 0.05 was considered statistically significant.
| |
Results |
|---|
|
|
|---|
EMT Expression in Human Bronchial Arterial and Rabbit Aortic SMCs
To examine whether EMT mRNA is expressed in human bronchial arterial and rabbit aortic SMCs, RT-PCR reactions were initiated as described in MATERIALS AND METHODS. Gel electrophoresis of the RT-PCR products showed bands of expected size. After gel-purification, both sense and antisense strands were sequenced. Sequence analysis of the product from human bronchial artery confirmed that it was a fragment of the published human EMT, perfectly matching positions 882 to 1,146 of the full-length cDNA. The isolated fragment contained sequences from several exons (4, 5, 6, and 7) of the human EMT gene (SLC22A3) (28) that further confirmed the amplification of mRNA rather than genomic sequences. Sequence analysis of the amplified rabbit product showed that it was similar to the human, rat, and mouse EMT cDNAs (Figure 1): nucleotide and amino-acid identity scores were at least 86 and 90%, respectively. This partial rabbit EMT cDNA sequence has been deposited in GenBank under the accession number AF294824.
|
Properties of NE Uptake by Rabbit Aortic SMCs
The supply of human lungs was limited, as was the yield of bronchial arterial SMCs from a single vessel. We therefore decided to use rabbit aortic SMCs to develop our NE uptake measurement technique and to get initial data for its sensitivity to steroids. This approach seemed justified because rabbit aortic SMCs also expressed mRNA for EMT and because bronchial arteries, which arise from the aorta, are part of the systemic circulation. Later, we confirmed these results in human bronchial arterial SMCs.
After enzymatic dispersion of rabbit aortic SMCs as described in MATERIALS AND METHODS, the majority of the cells had an elongated shape (Figure 2A). Freshly isolated cells remained elongated in incubation solution for at least 1 h (Figure 2B). Cells assumed a round shape after membrane depolarization with 20 mM KCl (Figure 2C) or adrenergic stimulation with 5 to 250 µM of NE (Figure 2D), indicative of SMC contraction as described by others (29). Measurements were taken only from contracted cells that all had similar shapes. Thus, the increase in fluorescence measured when cells exposed to increasing NE concentrations was not due to changes in cell shape. Cells exposed to NE and processed with SPG showed clear intracellular fluorescence with no indication of a fluorescent rim around the cells at any focal plane (Figure 3). The absence of such a rim suggests that the fluorescence was not due to NE binding to its surface receptor but in fact due to uptake of NE into the cell. When NE was poured onto slides and processed with SPG, a diffuse fluorescence was revealed. Thus, detection of fluorescence inside the cells with no surrounding background indicates that significant leakage of NE from the cells was unlikely to occur during SPG processing.
|
|
To assess whether the measured fluorescence correlated
with the actual intracellular NE concentration, permeabilized cells were equilibrated with defined NE concentrations. Because freshly dissociated SMCs insufficiently attached
to the carrier slide for this procedure and were lost during
permeabilization, cultured ovine airway epithelial cells (growing on collagen-coated glass coverslips) were used for these
experiments (30). The cells were fixed and permeabilized
with ice-cold methanol (used at
20°C twice for 5 min each
time), then were equilibrated with different NE concentrations (10 to 1,000 µM) for 20 min. The fluorescence of these
cells showed a nearly linear relation to the NE concentration in the 10- to 1,000-µM range (Figure 4).
|
To show that NE uptake by rabbit aortic SMCs is a time-dependent phenomenon (as expected for an uptake mechanism), cells were incubated in 50 µM NE for 5, 10, 20, 40, and 60 min. NE accumulation was detectable after 5 min of NE exposure and increased over time with a time course expected for a transporter (11, 12, 20, 31) (Figure 5, left panel ).
|
The concentration dependence of NE uptake was measured by exposing the rabbit aortic SMCs to different NE
concentrations (5, 25, 50, 100, and 250 µM). After a 20-min
incubation, NE uptake was detectable even at the lowest
NE concentration. There was a concentration-dependent
increase in NE uptake rates without a clear maximum
(Figure 5, middle panel ). In fact, using rate estimates of
NE uptake (assuming a linear relationship between fluorescence and NE concentration as validated in airway epithelial cells), we estimated the Michaelis constant (Km) for
this uptake mechanism to be around 245 µM NE (Figure
5, right panel ). This Km is in the range of the published Km
values for NE uptake (224 to 290 µM) in different non-neuronal cell types (25, 32, 33). Thus, our kinetic analysis
as well as the time course of NE uptake provide further
evidence that the detected NE fluorescence was intracellularly located, because binding of NE to its receptor occurs
quickly, would not be changing in this manner over time, and would not be expected to result in a Km of this magnitude (the reported dissociation constant of NE binding to
-adrenergic receptors in aorta is 60 nM [34]).
To examine whether intracellular NE-metabolizing enzymes had any influence on the measured fluorescence, cells were exposed to 50 µM NE for 20 min in the presence of 500 µM pargyline (MAO inhibitor) or 1 µM Ro-41-0960 (COMT inhibitor). These concentrations have been shown to be effective in other cell types (20, 35). In comparison with rabbit aortic SMCs exposed solely to 50 µM NE (N = 50 cells), both pargyline (N = 54 cells) and Ro 41-0960 (N = 62 cells) increased the average fluorescence values by only 1.31 ± 3.46 (7.1 ± 18% of controls) and 2.41 ± 2.69 (12.9 ± 14.4% of controls), respectively (P > 0.05 for both). This may be due to the fact that these enzymes were overwhelmed by these concentrations of NE as reported before (4).
Steroid Inhibition of NE Uptake by Rabbit Aortic SMCs
To see whether steroids have an effect on NE uptake, rabbit aortic SMCs were exposed to 50 µM NE for 20 min in
the presence or absence of different steroids. The NE concentration was chosen at 50 µM because MAO and
COMT inhibitors did not significantly change the measured intracellular NE accumulation at this concentration (see earlier text). Steroid hormones were used at 1 µM, the
concentration that produces 50% inhibition of effect of
corticosterone for NE uptake into rabbit aorta (31). After
20 min of coincubation with 50 µM NE, corticosterone,
hydrocortisone, and 17
-estradiol inhibited NE uptake
into SMCs by 68.8 ± 14.4, 39.9 ± 7.7, and 54.3 ± 13.7%,
respectively (means ± SEM for n = 3 experiments; all P < 0.05 versus NE-exposed controls) (Figure 6, left panel ).
|
The ability of steroids to inhibit NE uptake into SMCs within 20 min suggests a nongenomic mechanism of action. To provide additional evidence for this, the experiments were repeated with corticosterone rendered membrane-impermeant by conjugation to albumin (corticosterone-21-hemisuccinate-BSA [C-BSA]). After 20 min of coincubation with 50 µM NE, 1 µM C-BSA decreased NE uptake into SMCs by 62.3 ± 19.3% (mean ± SEM for n = 3 experiments; P < 0.05 versus NE-exposed controls; P > 0.05 versus NE plus corticosterone-exposed controls). To provide further evidence that transcription and protein synthesis were not required for corticosterone's action, experiments were repeated with 10 µM cycloheximide or 100 µM actinomycin D, concentrations shown to be effective in isolated arteries (36). Corticosterone inhibited NE uptake by 71.4 ± 6.8% in the presence of cycloheximide and 74.2 ± 1.6% in the presence of actinomycin D (means ± SEM for n = 3 experiments; all P > 0.05 versus NE- and corticosterone-treated controls) (Figure 6, right panel ). Therefore, the data presented here suggest that NE uptake by SMCs can be blocked by steroids acting through a nongenomic effect directly at the plasma membrane.
NE Uptake by Human Bronchial Arterial SMCs
The supply of human lungs and hence the yield of human bronchial arterial SMCs was limited for these studies. Therefore, a small number of experiments was performed. The cells were exposed to 50 µM NE with and without 1 µM corticosterone for 20 min. The bronchial arterial SMCs took up NE as expected and revealed fluorescence levels of 18.8 ± 0.8 arbitrary units (means ± SEM for n = 2 experiments); a value not significantly different from rabbit aortic SMCs, with 17.8 ± 0.7 arbitrary units (means ± SEM for n = 3 experiments). Corticosterone significantly inhibited NE uptake, reducing the fluorescence levels to 10.12 ± 1.23 arbitrary units (mean ± SEM for n = 2 experiments; P < 0.05 versus NE-exposed controls). The inhibition was less in human bronchial arterial SMCs than in rabbit cells (46.17 ± 6.5 versus 68.8 ± 14.4%, respectively). These data suggest that human bronchial arterial SMCs also express NE transporter that is functionally blocked by steroids.
| |
Discussion |
|---|
|
|
|---|
In the present study we showed that human bronchial arteries express mRNA of a steroid-sensitive membrane transporter for NE, namely EMT, and that SMCs freshly isolated from these vessels can take up NE in a steroid-sensitive fashion. Steroid sensitivity of NE uptake was further investigated in rabbit aortic SMCs that also expressed mRNA of EMT. The steroid effect occurred rapidly, was not altered by protein synthesis and transcription inhibitors, and could be reproduced with membrane-impermeant corticosterone. Together with our previous in vivo measurements (17, 37), these data suggest therefore that a steroid-sensitive NE uptake is likely to have an important role in the termination of noradrenergic signaling in the human bronchial circulation.
A newly developed single-cell assay was used to measure NE uptake by freshly isolated human bronchial arterial
and rabbit aortic SMCs. Although vascular tissue preparations have been extensively used for such measurements
before, tissues have the disadvantage of diffusion limitations through the extracellular space, leading to substrate
distribution inequalities (38). Uptake rates have also been
shown to differ depending on whether the catecholamine was applied to the intimal or adventitial side of the vessels (20). Using enzymatically dispersed, poly-L-lysine-immobilized cells and the modified SPG histofluorescence technique (24, 39), we eliminated these variables. Further, the
method described here allowed experiments with highly
limited numbers of SMCs (< 100 cells) that were freshly
isolated from small vessels (e.g., human bronchial arteries). We validated our single-cell NE uptake assay using
SMCs isolated from rabbit aorta, a more accessible systemic artery, by comparing the obtained results with the
readily available data of previous studies. We showed that:
(1) NE uptake was time-dependent, with a time course expected for an uptake mechanism as shown by others (11,
12, 20, 31); (2) NE uptake rate was concentration-dependent, with an estimated Km value in the range of those previously published (25, 32, 33); and (3) a near-linear correlation exists between NE concentrations and measured
fluorescence. The experimental NE concentrations (5 to
250 µM) used to measure NE uptake and the steroid inhibition in human bronchial arterial and rabbit aortic SMCs
were in the estimated range of the neuromuscular junctional NE concentrations (i.e., approximately 200 to 300 µM
initially, and
10 µM finally) (40), thereby providing
physiologically relevant information about the role of NE
uptake in sympathetic neurotransmission.
The rapid inhibition of NE uptake into human bronchial arterial and rabbit aortic SMCs suggests a nongenomic mechanism of action. This would not require changes in gene expression (for review, see 41-43) and more readily explains the rapid inhibition of NE uptake. Our additional data (insensitivity to transcription and protein synthesis inhibitors, activity of the macromolecule-coupled steroid) confirm unambiguously that steroids inhibit NE uptake by rabbit aortic SMCs via a plasma membrane effect. Other acute/rapid nongenomic steroid actions have been linked to a change in membrane potential resulting from activation of maxi-K channels (44), the inhibition of L-Ca2+ channels (45), an increase in the membrane binding of calmodulin (46), and changes in the lipid composition of the plasma membrane (36). The exact link between nongenomic steroid action and the inhibition of NE uptake by SMCs needs further elucidation.
We showed the expression of mRNA for a membrane transporter, namely EMT, in both human bronchial arteries and rabbit aorta. RNA samples for RT-PCR were extracted from the media of these vessels, therefore the possibility of EMT mRNA amplification from cells other than SMCs (e.g., fibroblasts, nerves) is possible but unlikely. Inasmuch as EMT is known to transport NE (11), it may be the primary transporter responsible for the NE uptake by SMCs in both human bronchial arteries and rabbit aorta. EMT expression further confirms the functional measurements of NE uptake. Although two other membrane transporters, OCT1 and OCT2, have been shown to mediate NE uptake processes by non-neuronal cells (for review, see 47-49), our data show that NE uptake by human bronchial arterial and rabbit aortic SMCs occurs through either OCT2 or EMT because steroids blocked NE uptake by these cells at concentrations not expected to block OCT1 (50). Because OCT2 has shown to be primarily restricted to kidney (8, 10) with detectable expression in the spleen, placenta, intestine, and brain (10, 51), the uptake mechanism in SMCs is most likely due to EMT. Further, because OCT1 and OCT2 have not been found in the lung and EMT is expressed in human bronchial arteries, we think that EMT is the steroid target in these vessels.
In summary, our data show that GSs interfere with NE
uptake by SMCs freshly isolated from human bronchial arteries. This could consequently increase NE concentration
at
-adrenergic receptor sites of the bronchial vascular
smooth muscle. The rapid inhibitory effect of GSs, which
was demonstrated on large conduit vessels, may also potentiate the
-adrenergic responsiveness in resistance vessels of the bronchial vasculature and decrease blood flow. Therefore, although other, alternative mechanisms may be
involved (52, 53), we suggest that the inhibitory effect of
GSs on NE uptake could explain or contribute to the
1-adrenergic antagonist-blockable, rapid, and transient bronchial vasoconstriction measured after inhaled GS in vivo.
| |
Footnotes |
|---|
Address correspondence to: Adam Wanner, M.D., Div. of Pulmonary and Critical Care Medicine, University of Miami School of Medicine, P.O. Box 016960 (R-47), Miami, FL 33101. E-mail: awanner{at}miami.edu
(Received in original form March 12, 2001 and in revised form May 9, 2001).
Abbreviations: complementary DNA, cDNA; catecholamine-O-methyltransferase, COMT; differential-interference-contrast, DIC; extraneuronal monoamine transporter, EMT; mean fluorescence intensity value, FN; glucocorticosteroid, GS; Michaelis constant, Km; monoamine oxidase, MAO; messenger RNA, mRNA; norepinephrine, NE; organic cation transporter, OCT; reverse transcriptase/polymerase chain reaction, RT-PCR; standard error of the mean, SEM; smooth muscle cell, SMC; sucrose- potassium phosphate-glyoxylic acid, SPG.Acknowledgments: This work was supported by NIH grants HL58086 (A.W.) and NIH HL60644 (M.S.), and an award from the American Heart Association, Florida/Puerto Rico Affiliate. G.H. is a recipient of a fellowship from the Hungarian Pulmonary Foundation.
| |
References |
|---|
|
|
|---|
1. Butler, J. 1992. The bronchial circulation. In Lung Biology in Health and Disease. Marcel Dekker, New York.
2. Bonisch, H., and L. Eiden. 1998. Catecholamine reuptake and storage. Overview. Adv. Pharmacol. 42: 149-164 .
3. Iversen, L. L., and P. J. Salt. 1970. Inhibition of catecholamine uptake-2 by steroids in the isolated rat heart. Br. J. Pharmacol. 40: 528-530 [Medline].
4. Trendelenburg, U. 1988. The extraneuronal uptake and metabolism of catecholamines. In Catecholamines I, Handbook of Experimental Pharmacology 90/I. U. Trendelenburg and N. Weiner, editors. Spinger, New York. 279-319.
5. Grundemann, D., V. Gorboulev, S. Gambaryan, M. Veyhl, and H. Koepsell. 1994. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372: 549-552 [Medline].
6.
Nagel, G.,
C. Volk,
T. Friedrich,
J. C. Ulzheimer,
E. Bamberg, and
H. Koepsell.
1997.
A reevaluation of substrate specificity of the rat cation
transporter rOCT1.
J. Biol. Chem.
272:
31953-31956
7. Breidert, T., F. Spitzenberger, D. Grundemann, and E. Schomig. 1998. Catecholamine transport by the organic cation transporter type 1 (OCT1). Br. J. Pharmacol. 125: 218-224 [Medline].
8. Okuda, M., H. Saito, Y. Urakami, M. Takano, and K. Inui. 1996. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun. 224: 500-507 [Medline].
9.
Grundemann, D.,
J. Babin-Ebell,
F. Martel,
N. Ording,
A. Schmidt, and
E. Schomig.
1997.
Primary structure and functional expression of the apical
organic cation transporter from kidney epithelial LLC-PK1 cells.
J. Biol.
Chem.
272:
10408-10413
10. Gorboulev, V., J. C. Ulzheimer, A. Akhoundova, I. Ulzheimer-Teuber, U. Karbach, S. Quester, C. Baumann, F. Lang, A. E. Busch, and H. Koepsell. 1997. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16: 871-881 [Medline].
11. Grundemann, D., B. Schechinger, G. A. Rappold, and E. Schomig. 1998. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci. 1: 349-351 . [Medline]
12.
Kekuda, R.,
P. D. Prasad,
X. Wu,
H. Wang,
Y. J. Fei,
F. H. Leibach, and
V. Ganapathy.
1998.
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly
expressed in placenta.
J. Biol. Chem.
273:
15971-15979
13. Verhaagh, S., N. Schweifer, D. P. Barlow, and R. Zwart. 1999. Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics 55: 209-218 [Medline].
14. Rajan, P. D., R. Kekuda, C. D. Chancy, W. Huang, V. Ganapathy, and S. B. Smith. 2000. Expression of the extraneuronal monoamine transporter in RPE and neural retina. Curr. Eye Res. 20: 195-204 [Medline].
15.
Wu, X.,
W. Huang,
M. E. Ganapathy,
H. Wang,
R. Kekuda,
S. J. Conway,
F. H. Leibach, and
V. Ganapathy.
2000.
Structure, function, and regional
distribution of the organic cation transporter OCT3 in the kidney.
Am. J. Physiol. Renal Physiol.
279:
F449-458
.
16. Martel, F., D. Grundemann, C. Calhau, and E. Schomig. 2001. Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn Schmiedebergs Arch. Pharmacol. 363: 40-49 [Medline].
17.
Kumar, S. D.,
J. L. Brieva,
I. Danta, and
A. Wanner.
2000.
Transient effect
of inhaled fluticasone on airway mucosal blood flow in subjects with and
without asthma.
Am. J. Respir. Crit. Care Med.
161:
918-921
18. Obst, O. O., M. C. Linssen, G. J. Van der Vusse, and H. Kammermeier. 1996. Interstitial noradrenaline concentration of rat hearts as influenced by cellular catecholamine uptake mechanisms. Mol. Cell. Biochem. 163- 164:173-180.
19. Gulati, O. D., and N. Sivaramakrishna. 1975. Kinetics and some characteristics of uptake of noradrenaline by the human umbilical artery. Br. J. Pharmacol. 53: 152-154 [Medline].
20. Henseling, M.. 1983. Kinetic constants for uptake and metabolism of 3H- (-)noradrenaline in rabbit aorta. Possible falsification of the constants by diffusion barriers within the vessel wall. Naunyn Schmiedebergs Arch. Pharmacol. 323: 12-23 [Medline].
21. Martel, F., I. Azevedo, and W. Osswald. 1993. Extraneuronal uptake and O-methylation of 3H-adrenaline in the rabbit aorta. Naunyn Schmiedebergs Arch. Pharmacol. 347: 363-370 [Medline].
22. Morris, R. G., M. G. Venning, and I. S. de la Lande. 1988. Influence of uptake1 and uptake2 on the relationship between diffusion and metabolism of noradrenaline in the perfused rabbit ear artery. Blood Vessels 25: 217-231 [Medline].
23. Clapp, L. H., and A. M. Gurney. 1991. Outward currents in rabbit pulmonary artery cells dissociated with a new technique. Exp. Physiol. 76: 677-693 [Abstract].
24. Torre, J. C., and J. W. Surgeon. 1976. A methodological approach to rapid and sensitive monoamine histofluorescence using a modified glyoxylic acid technique: the SPG method. Histochemistry 49: 81-93 [Medline].
25. Bryan, L. J., and S. R. O'Donnell. 1980. Affinities of catecholamines for extraneuronal uptake in smooth muscle cells in trachealis muscle of guinea-pig. Naunyn Schmiedebergs Arch. Pharmacol. 311: 139-146 [Medline].
26. Bryan, L. J., and S. R. O'Donnell. 1980. Methodological aspects of the use of fluorescence microphotometry to study the extraneuronal uptake of catecholamines. J. Pharmacol. Methods 4: 29-42 [Medline].
27. Bryan, L. J., and S. R. O'Donnell. 1981. Kinetic analyses of the mechanisms of action of inhibitors of the extraneuronal uptake of adrenaline in smooth muscle cells of guinea-pig trachea. Naunyn Schmiedebergs Arch. Pharmacol. 315: 249-254 [Medline].
28. Grundemann, D., and E. Schomig. 2000. Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Hum. Genet. 106: 627-635 [Medline].
29. Kwan, C. Y., V. Gaspar, I. Berezin, A. M. Low, and E. E. Daniel. 1992. Morphological and functional characterization of vascular muscle cells enzymatically dispersed from dog mesenteric arteries. J. Vasc. Res. 29: 450-460 [Medline].
30. Lieb, T., R. Forteza, and M. Salathe. 2000. Hyaluronic acid in cultured ovine tracheal cells and its effect on ciliary beat frequency in vitro. J. Aerosol Med. 13: 231-238 [Medline].
31. Schomig, E., and C. L. Schonfeld. 1990. Extraneuronal noradrenaline transport (uptake2) in a human cell line (Caki-1 cells). Naunyn Schmiedebergs Arch. Pharmacol. 341: 404-410 [Medline].
32. Obst, O. O., H. Rose, and H. Kammermeier. 1996. Characterization of catecholamine uptake2 in isolated cardiac myocytes. Mol. Cell. Biochem. 163- 164:181-183.
33. Grohmann, M., and U. Trendelenburg. 1984. The substrate specificity of uptake2 in the rat heart. Naunyn Schmiedebergs Arch. Pharmacol. 328: 164-173 [Medline].
34. Heaslip, R. J., and R. G. Rahwan. 1983. Norepinephrine-induced contractions of the rat aorta in the absence of extracellular calcium. I. Effects of alpha-adrenoreceptor blockers. Gen. Pharmacol. 14: 497-503 [Medline].
35. Percy, E., D. M. Kaye, G. W. Lambert, S. Gruskin, M. D. Esler, and X. J. Du. 1999. Catechol-O-methyltransferase activity in CHO cells expressing norepinephrine transporter. Br. J. Pharmacol. 128: 774-780 [Medline].
36. Shaw, L., M. J. Taggart, and C. Austin. 2000. Mechanisms of 17 beta-oestradiol induced vasodilatation in isolated pressurized rat small arteries. Br. J. Pharmacol. 129: 555-565 [Medline].
37.
Brieva, J. L.,
I. Danta, and
A. Wanner.
2000.
Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma.
Am. J. Respir.
Crit. Care Med.
161:
293-296
38. Trendelenburg, U., H. Fleig, L. J. Bryan, and H. Bonisch. 1983. The extraneuronal compartments for the distribution of isoprenaline in the rat heart. Naunyn Schmiedebergs Arch. Pharmacol. 324: 169-179 [Medline].
39. de la Torre, J. C.. 1980. Standardization of the sucrose-potassium phosphate-glyoxylic acid histofluorescence method for tissue monoamines. Neurosci. Lett. 17: 339-340 [Medline].
40. Stjarne, L., and E. Stjarne. 1995. Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Prog. Neurobiol. 47: 45-94 [Medline].
41. Watson, C. S., and B. Gametchu. 1999. Membrane-initiated steroid actions and the proteins that mediate them. Proc. Soc. Exp. Biol. Med. 220: 9-19 [Abstract].
42. Chen, H. C., and R. V. Farese. 1999. Steroid hormones: interactions with membrane-bound receptors. Curr. Biol. 9: R478-R481 [Medline].
43. Schmidt, B. M., D. Gerdes, M. Feuring, E. Falkenstein, M. Christ, and M. Wehling. 2000. Rapid, nongenomic steroid actions: a new age? Front. Neuroendocrinol. 21: 57-94 [Medline].
44.
Valverde, M. A.,
P. Rojas,
J. Amigo,
D. Cosmelli,
P. Orio,
M. I. Bahamonde,
G. E. Mann,
C. Vergara, and
R. Latorre.
1999.
Acute activation of
Maxi-K channels (hSlo) by estradiol binding to the beta subunit.
Science
285:
1929-1931
45.
Ruehlmann, D. O.,
J. R. Steinert,
M. A. Valverde,
R. Jacob, and
G. E. Mann.
1998.
Environmental estrogenic pollutants induce acute vascular
relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells.
FASEB J.
12:
613-619
46. Sze, P. Y., and Z. Iqbal. 1994. Regulation of calmodulin content in synaptic plasma membranes by glucocorticoids. Neurochem. Res. 19: 1455-1461 [Medline].
47. Koepsell, H., V. Gorboulev, and P. Arndt. 1999. Molecular pharmacology of organic cation transporters in kidney. J. Membr. Biol. 167: 103-117 [Medline].
48. Sweet, D. H., and J. B. Pritchard. 1999. The molecular biology of renal organic anion and organic cation transporters. Cell Biochem. Biophys. 31: 89-118 . [Medline]
49.
Burckhardt, G., and
N. A. Wolff.
2000.
Structure of renal organic anion and
cation transporters.
Am. J. Physiol. Renal Physiol.
278:
F853-F866
.
50. Martel, F., L. Ribeiro, C. Calhau, and I. Azevedo. 1999. Comparison between uptake2 and rOCT1: effects of catecholamines, metanephrines and corticosterone. Naunyn Schmiedebergs Arch. Pharmacol. 359: 303-309 [Medline].
51.
Busch, A. E.,
U. Karbach,
D. Miska,
V. Gorboulev,
A. Akhoundova,
C. Volk,
P. Arndt,
J. C. Ulzheimer,
M. S. Sonders,
C. Baumann,
S. Waldegger,
F. Lang, and
H. Koepsell.
1998.
Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.
Mol. Pharmacol.
54:
342-352
52.
Ullian, M. E..
1999.
The role of corticosteriods in the regulation of vascular
tone.
Cardiovasc. Res.
41:
55-64
53. Brem, A. S.. 2001. Insights into glucocorticoid-associated hypertension. Am. J. Kidney Dis. 37: 1-10 [Medline].
This article has been cited by other articles:
![]() |
E. Livingston, R. Chaudhuri, A. D. McMahon, I. Fraser, C. P. McSharry, and N. C. Thomson Systemic sensitivity to corticosteroids in smokers with asthma Eur. Respir. J., January 1, 2007; 29(1): 64 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Horvath, N. Schmid, M. A. Fragoso, A. Schmid, G. E. Conner, M. Salathe, and A. Wanner Epithelial Organic Cation Transporters Ensure pH-Dependent Drug Absorption in the Airway Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 53 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chaudhuri, E. Livingston, A. D. McMahon, J. Lafferty, I. Fraser, M. Spears, C. P. McSharry, and N. C. Thomson Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 127 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Horvath and A. Wanner Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma Eur. Respir. J., January 1, 2006; 27(1): 172 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Horvath, Z. Sutto, A. Torbati, G. E. Conner, M. Salathe, and A. Wanner Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L829 - L837. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.S. Mendes, A. Pereira, I. Danta, R.C. Duncan, and A. Wanner Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids Eur. Respir. J., June 1, 2003; 21(6): 989 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Horvath, A. Torbati, G. E. Conner, M. Salathe, and A. Wanner Systemic Ovalbumin Sensitization Downregulates Norepinephrine Uptake by Rabbit Aortic Smooth Muscle Cells Am. J. Respir. Cell Mol. Biol., December 1, 2002; 27(6): 746 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.A. Acuna, J. Gabrijelcic, E.M. Uribe, R. Rabinovich, J. Roca, J.A. Barbera, K.F. Chung, and R. Rodriguez-Roisin Fluticasone propionate attenuates platelet-activating factor-induced gas exchange defects in mild asthma Eur. Respir. J., May 1, 2002; 19(5): 872 - 878. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |